Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan analyst Anupam Rama maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and lowers the price target ...
UBS analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $85 to ...
Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and raises the price target from ...
Goldman Sachs analyst Salveen Richter maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target...
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target fro...
Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.
Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan f...
Apellis To Host Conference Call At 8:00 AM ET
